Salwa Mansour

Ms. Salwa Mansour


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2019 in Acta Neuropathologica
Verified
Journal Article
Closed access
PDF file
CVCristina Vergara
Cristina Vergara
SHSarah Houben
Sarah Houben
VSValérie Suain
Valérie Suain
ZYZehra Yilmaz
Zehra Yilmaz
RDRobert De Decker
Robert De Decker
JBJean-Pierre Brion
Jean-Pierre Brion

10 January 2020 in Acta Neuropathologica
Verified
Journal Article
Closed access
PDF file
KAKunie Ando
Kunie Ando
RDRobert De Decker
Robert De Decker
CVCristina Vergara
Cristina Vergara
ZYZehra Yilmaz
Zehra Yilmaz
SMSalwa Mansour
Salwa Mansour
JBJean-Pierre Brion
Jean-Pierre Brion

4 June 2024 in Acta Neuropathologica
Verified
Journal Article
Open access
PDF file
KAKunie Ando
Kunie Ando
FKFahri Küçükali
Fahri Küçükali
EDEmilie Doeraene
Emilie Doeraene
SNSiranjeevi Nagaraj
Siranjeevi Nagaraj
EAEugenia Maria Antonelli
Eugenia Maria Antonelli
BNBrain Bank NeuroCEB Neuropathology Network
Brain Bank NeuroCEB Neuropathology Network
A recent large genome-wide association study has identified EGFR (encoding the epidermal growth factor EGFR) as a new genetic risk factor for late-onset AD. SHIP2, encoded by INPPL1, is taking part in the signalling and interactome of several growth factor receptors, such as the EGFR. While INPPL1 has been identified as one of the most significant genes whose RNA expression correlates with cognitive decline, the potential alteration of SHIP2 expression and localization during the progression of AD remains largely unknown. Here we report that gene expression of both EGFR and INPPL1 was upregulated in AD brains. SHIP2 immunoreactivity was predominantly detected in plaque-associated astrocytes and dystrophic neurites and its increase was correlated with amyloid load in the brain of human AD and of 5xFAD transgenic mouse model of AD. While mRNA of INPPL1 was increased in AD, SHIP2 protein undergoes a significant solubility change being depleted from the soluble fraction of AD brain homogenates and co-enriched with EGFR in the insoluble fraction. Using FRET-based flow cytometry biosensor assay for tau-tau interaction, overexpression of SHIP2 significantly increased the FRET signal while siRNA-mediated downexpression of SHIP2 significantly decreased FRET signal. Genetic association analyses suggest that some variants in INPPL1 locus are associated with the level of CSF pTau. Our data support the hypothesis that SHIP2 is an intermediate key player of EGFR and AD pathology linking amyloid and tau pathologies in human AD.

14 July 2020 in Frontiers in Molecular Neuroscience
Verified
Journal Article
Open access
PDF file
SHSarah Houben
Sarah Houben
MFMarie-Ange de Fisenne
Marie-Ange de Fisenne
KAKunie Ando
Kunie Ando
VDVirginie Vanden Dries
Virginie Vanden Dries
LPLuc Poncelet
Luc Poncelet
KLKarelle Leroy
Karelle Leroy
Alzheimer’s disease (AD) is characterized by the accumulation in the brain of intraneuronal aggregates of abnormally and hyperphosphorylated tau proteins and of extracellular deposits of amyloid-β surrounded by dystrophic neurites. Numerous experimental models have shown that tau pathology develops in the brain after intracerebral injection of brain homogenates or pathological tau [paired helical filaments (PHF)-tau)] from AD brains. Further investigations are however necessary to identify or exclude potential extracerebral routes of tau pathology transmission, e.g., through the intravascular route. In this study, we have analyzed the effect of intravenous injection of PHF-tau proteins from AD brains on the formation of tau and amyloid pathologies in the brain of wild-type (WT) mice and of 5XFAD mice (an amyloid model). We observed that 5XFAD mice with a disrupted blood–brain barrier showed increased plaque-associated astrogliosis, microgliosis, and increased deposits of Aβ40 and Aβ42 after intravenous injection of PHF-tau proteins. In addition, an increased phosphotau immunoreactivity was observed in plaque-associated dystrophic neurites. These results suggest that blood products contaminated by PHF-tau proteins could potentially induce an exacerbation of neuroinflammation and AD pathologies.

1 January 2018 in Frontiers in Neuroscience
Verified
Journal Article
Open access
CVCristina Vergara
Cristina Vergara
SHSarah Houben
Sarah Houben
VSValérie Suain
Valérie Suain
ZYZehra Yilmaz
Zehra Yilmaz
RDRobert De Decker
Robert De Decker
JBJean-Pierre Brion
Jean-Pierre Brion
The topographical development of tau pathology in Alzheimer’s Disease (AD) progresses by following neuroanatomically connected areas, suggesting that spreading of tau pathology occurs by transmission of abnormal tau between synaptically connected cells. Both, neuropathological analysis in AD and experimental evidence in transgenic models overexpressing FTDP-17 mutant tau, suggest that amyloid pathology can accelerate the development of tau pathology, yet the involved mechanisms are not understood. To investigate a potential role of Aß pathology in accelerating the spreading of tau pathology independently of the overexpression of a FTDP-17 mutant tau, we compared development of tau pathology after stereotaxic injection in the somatosensory cortex of short-length native human PHF. We used four mouse lines, namely non-transgenic wild-type, APP/PS1 overexpressing human mutant APP and PS1, APP knock-out mice and tau knock-out mice. Gallyas and phosphotau positive grain-like tau inclusions developed in wild-type, APP/PS1 and APP knock-out mice but not in tau knock-out mice. Ultrastructural analysis demonstrated that these tau grains were intracellular and were made of 20 nm straight filaments. These tau grains seeded by human PHF-tau were composed only of endogenous murine tau. Ipsilateral anteroposterior and contralateral spreading of these tau grains in the cortex was more important in APP/PS1 than in wild-type mice. Importantly, the formation of enlarged, tau positive, plaque-associated dystrophic neurites was observed in APP/PS1 mice injected with human PHF but never in non-injected APP/PS1 mice. These data demonstrate in vivo that the presence of Aß pathology enhances experimentally induced tau seeding of endogenous, wild-type tau expressed at physiological level, and demonstrate the fibrillar nature of heterotopically seeded endogenous tau. These observations strongly support the hypothesis that a cross-talk between Aß and tau can enhance the development of tau pathology in AD through increased tau spreading. Summary: Alzheimer's disease is the main cause of dementia, causing progressive memory decline and behavioral changes affecting daily tasks. It is characterised by the appearance of two abnormal lesions called amyloid plaques and tangles, responsible for the neuronal loss during the disease. Amyloid plaques are composed of a small protein called amyloid-beta, and tangles are formed by the aggregation of another protein called tau. Here we study how amyloid-beta affects the aggregation of tau to form tangles in genetically modified animal models.

26 January 2026 in Cells
Verified
Journal Article
Open access
PDF file
KAKunie Ando
Kunie Ando
Lidia Lopez López GutiérrezLidia Lopez López Gutiérrez
Lidia Lopez López Gutiérrez
SMSalwa Mansour
Salwa Mansour
ZYZehra Yilmaz
Zehra Yilmaz
LDLuce Dauphinot
Luce Dauphinot
KLKarelle Leroy
Karelle Leroy
Phosphatidylinositol-binding clathrin assembly protein (PICALM) is a clathrin adaptor essential for clathrin-mediated endocytosis. Genome-wide association studies (GWAS) have consistently identified PICALM as one of the most significant genetic susceptibility loci for late-onset sporadic Alzheimer’s disease (AD). However, the functional impact of the most validated AD-associated variant, rs3851179, remains unclear. Here, we examined PICALM mRNA and protein expression in post-mortem AD brains with reference to rs3851179 genotype. We found that PICALM mRNA levels were significantly increased in AD brains compared with controls, and that the protective rs3851179T allele was associated with reduced PICALM mRNA levels relative to the non-protective rs3851179C allele. In contrast, PICALM levels were significantly reduced in AD brain lysates compared with controls. PICALM expression did not significantly differ between carriers of the protective and non-protective alleles. Analysis of the mRNA-to-protein ratio revealed a significant dissociation between transcript and protein levels, suggesting relatively reduced protein expression efficiency in cases carrying the non-protective CC genotype. To assess whether reduced PICALM levels influence tau pathology, we used Picalm heterozygous knockout (Picalm+/−) mice, which express approximately 50% of the wild-type Picalm protein. Following stereotaxic injection of pathological tau extracted from AD brains, both wild-type and Picalm+/− mice developed tau pathology; however, the extent of tau accumulation did not significantly differ between genotypes. Together, these findings indicate that although PICALM protein level is reduced in AD, this reduction does not appear to affect tau propagation in this model. Therefore, the AD susceptibility associated with PICALM variant likely arises from mechanisms other than tau spread, possibly involving other aspects of autophagy, endocytic or vascular function.